Safflower-containing traditional Chinese medicine for treating hemiplegic paralysis

Abstract

The invention provides a safflower-containing traditional Chinese medicine for treating hemiplegic paralysis. On the basis of a traditional remedy, the inventor does a lot of researches and experiments and finds out that six types of drugs including safflower, fructus amomi, ficus formosana root, ramulus et uncus uncariae, caulis sargentodoxae and phyllostachys heteroclada root are combined and the drugs are combined to enable all drug effects to have a synergistic effect so that the hemiplegic paralysis can be effectively treated.

Description

Technical field: [0001] The invention relates to a traditional Chinese medicine, in particular to a traditional Chinese medicine containing safflower for treating hemiplegia. Background technique: [0002] Hemiplegia is one of the common and frequently-occurring diseases of middle-aged and elderly people. Its morbidity rate is high, the mortality rate is high, and the disability rate is high. The onset of hemiplegia is acute. etc. Now there are many drugs used to treat hemiplegia, such as: Naoshuan Kangfu Capsules, Cerebral Thrombosis Tablets, etc. In clinical application, these drugs not only treat cerebral hemorrhage, but also treat cerebral stasis, but these drugs do not specifically treat hemiplegia. The medicine of hemiplegia late stage (recovery period), therefore the market is badly in need of developing a kind of medicine for the treatment of cerebral hemiplegia convalescent period, and its treatment purpose is to promote the recovery of function, reduce sequelae, im...

AI Technical Summary

Problems solved by technology

[0002] Hemiplegia is one of the common and frequently-occurring diseases of middle-aged and elderly people. Its morbidity rate is high, the mortality rate is high, and the disability rate is high. The onset of hemiplegia is acute. etc. Now there are many drugs used to treat hemiplegia, such as: Naoshuan Kangfu Capsules, Cerebral Thrombosis Tablets, etc. In clinical application, these drugs not only treat cerebral hemorrhage, but also treat cerebral stasis, but these drugs do not specifically treat Drugs for the late stage (recovery period) of hemiplegia, so the market urgently needs to develop a drug for the treatment of cerebral hemiplegia in the recovery period. The purpose of treatment is to promote the recovery of functions, reduce sequelae, and improve the patient's working ability and quality of life.